ELEKTA AB (publ)
Corporate organization number 556170-4015
Kungstensgatan 18 – Box 7593 – SE 103 93 Stockholm

Six-month interim report May – October 2006/07



- **Order bookings rose 15 percent to SEK 2,302 M (1,997). Order backlog amounted to SEK 4,147 M, a record high level.**
- **Net sales increased 4 percent to SEK 2,014 M (1,940).**
- **Operating profit increased to SEK 159 M (153) and the operating margin was 8 percent (8). On a rolling 12-month basis, the operating margin was 10 percent.**
- **Profit after taxes amounted to SEK 104 M (98). Earnings per share after dilution amounted to SEK 1.11 (1.03).**
- **Cash flow after investments was negative SEK 343 M (neg. 51). Acquisition was included with SEK 144 M.**
- **Strong interest in Leksell Gamma Knife® Perfexion™ has resulted in a total of 10 orders received.**

ELEKTA

Elekta's operations

Elekta is an international medical technology Group, providing advanced clinical solutions, comprehensive information systems and services for efficient and high precision treatment of cancer and brain disorders. Elekta's solutions are used at over 4,000 hospitals around the world. Elekta is the world leader in image guided and stereotactic clinical solutions for radiosurgery and radiation therapy, methods for treating tumors and functional targets with ultrahigh precision while sparing healthy tissue. All of Elekta's solutions employ non-invasive or minimally invasive techniques. This means that in addition to being clinically effective, these solutions are also cost-effective and gentle on the patient. The Elekta Group is also the world's largest supplier of software solutions across the spectrum of cancer care.

Market outlook

The total market for Elekta's clinical solutions, IT systems and services is expected to grow by 5-10 percent annually, and the demand for Elekta's clinical solutions remains strong. However, the high value of individual orders and order coordination within the framework of health care investment programs often lead to significant quarterly variations in business volume.

The market development is driven by an increased incidence of cancer and by the shortage of treatment capacity that is prevailing in most countries. The number of newly diagnosed cancer cases per year, is expected to increase by 50 percent during the next 20 years, primarily as a result of a higher average age. The number of cancer patients receiving radiation treatment, often in combination with other treatment methods, is steadily increasing and is at around 50 percent in developed countries. New advanced, more precise and accurate methods are expected to increase the role of radiation therapy in the future.

Important events

- Elekta continues to install Elekta Synergy® for image guided radiation therapy around the world in a rapid pace and continues to strengthen its leading position in this new method for treating cancer with higher precision and accuracy.
- In August, Elekta received the necessary governmental approvals for finalizing the acquisition of 80 percent of Beijing Medical Equipment Institute (BMEI). This acquisition strengthens Elekta's position on the Chinese market for radiation therapy solutions and brings to Elekta the ability to meet the needs of the Chinese and other emerging markets for less capital-intensive radiation therapy solutions.
- The market introduction of Leksell Gamma Knife® Perfexion™ is continuing according to plan, with substantial interest from current Gamma Knife users as well as from new prospects. Previously, Elekta has booked and disclosed six (6) orders for Leksell Gamma Knife® Perfexion™, a majority to be delivered within this fiscal year.
- In addition to the orders already communicated, Elekta have booked orders for an additional four (4) Leksell Gamma Knife Perfexion, all for delivery within this fiscal year. Two of these four orders have been booked in Q2.
- In October, Elekta received an order from St Luke's Hospital in Dublin, Ireland, valued at over EUR 10 M, and including, among other items, four Elekta Synergy® systems.
- In November, Elekta received the prestigious assignment, within a private financing initiative (PFI) to equip the new Somerset Oncology & Haematology Centre at Taunton & Somerset NHS Trust's Musgrove Park Hospital, with advanced digital linear accelerators for radiation therapy, as well as software systems for treatment planning and information man-

agement. The total contract is valued at approx. SEK 335 M over 30 years, of which SEK 110 M has been booked as order in Q3 of Elekta's fiscal year.

- In October and November respectively, the European and the American Societies for Therapeutic Radiology and Oncology (ESTRO and ASTRO) held their annual meetings. These are the two largest scientific meetings in radiation oncology and for the industry the most important events when suppliers can meet their customers. Both these meetings were resounding successes for Elekta, with record high interest in not least Elekta Synergy and in Elekta's solutions for stereotactic radiation therapy.

Order bookings and order backlog

Order bookings for the six-month period rose 15 percent to SEK 2,302 M (1,997). Elekta BMEI, acquired in August 2006, contributed with SEK 10 M. Based on unchanged exchange rates order booking rose 20 percent.

Based on unchanged exchange rates order bookings in North and South America rose 26 percent, region Europe, including Middle East and Africa, rose 13 percent and Asia rose 20 percent.

Order bookings rose by 26 percent during the second quarter to SEK 1,315 M (1,045).

Order bookings for the rolling 12 months increased by 24 percent.

The order backlog was on October 31, 2006 on an all time high level of SEK 4,147 M, compared with SEK 3,875 M on April 30, 2006.



Order bookings SEK M	Quarter 2 2006/07	Quarter 2 2005/06	Change	6 months 2006/07	6 months 2005/06	Change	Rolling 12 months	Change
Europe, Middle East, Africa	430	320	34%	801	720	11%	1,792	13%
North and South America	660	489	35%	1,061	883	20%	2,347	34%
Asia	225	236	-5%	440	394	12%	871	24%
Group	**1,315**	**1,045**	**26%**	**2,302**	**1,997**	**15%**	**5,010**	**24%**

ELEKTA

Market comments

North and South America

The North American market is primarily driven by the increased cancer incidence and by the rapid acceptance of new and refined treatment methods such as image guided radiation therapy (IGRT) and stereotactic radiation therapy (SRT). The strong interest for these methods is triggered by the expected improvements in clinical efficacy and cost efficiency.

Elekta's leading position in image guided radiation therapy, together with Elekta's ability to supply treatment equipment and information management systems as one comprehensive and integrated offer, have substantially strengthened Elekta's position on the North American market.

In the US market, efficiency in patient flows and processing of clinical data are often decisive sales arguments. Software systems that handle both the entire treatment process and administration and resource allocation are therefore required in most sales situations. Elekta's IMPAC systems are now included in most linear accelerator orders and IMPAC branded software systems are expanding into medical oncology and across the spectrum of cancer care.

The market introduction of Leksell Gamma Knife® Perfexion™ has been met with a substantial interest, both from current Gamma Knife® users and from new potential customers.

Europe, including Middle East and Africa

Elekta's position in the European market is strong. The European market for radiation therapy is driven primarily by the lack of care capacity and therapeutic equipment. In many European countries, the number of linear accelerators per capita is less than half that of the US. Several countries, including the UK, France and Ireland, have national investment programs for increasing treatment capacity in cancer care. Several countries are showing interest in the private financing of public care (Private Financing Initiative, PFI) model that have been established in the United Kingdom. Collaborations between public and private financiers are expected to become more common in several European countries and Elekta's ability to provide comprehensive and integrated solutions, yet based on industry standards and open connectivity, makes the company an attractive partner in such projects.

There is a substantial demand in Europe for information systems for cancer care, particularly for the purpose of improving productivity, streamlining operations and multi-site connectivity. Elekta therefore continues to introduce IMPAC systems on more markets in Europe, with consideration taken to installation and service resources.

The market introduction of Leksell Gamma Knife® Perfexion™ has been met with a substantial interest, both from current Gamma Knife® users and from new potential customers.

Asia

In China, Elekta is the market leader in advanced radiation therapy solutions. The acquisition of 80 percent of Beijing Medical Equipment Institute (BMEI) will further strengthen Elekta's position on the Chinese market, making Elekta a comprehensive provider of linear accelerators across the spectrum of price and performance specifications. BMEI brings to Elekta the ability to fully meet the needs of the Chinese and other emerging markets for affordable cancer management solutions.

In June, Elekta received regulatory approval in Japan for Elekta Synergy® and a number of important reference centers has now been established. Building on these, Elekta expects to be able to increase the market share in radiation therapy systems. There is a substantial potential in Japan for upgrades to Leksell Gamma Knife® Perfexion™, but the long process for regulatory approval, means that Elekta expects to be able to introduce this new system in mid 2007.

In China, the healthcare system is currently under reform and restructuring, in order to meet the growing need for advanced care and to make these services more accessible to a lager part of the population. As a result, the long-standing market growth in China has temporarily weakened.

Long-term, there is a strong rationale for a continued rapid growth in the Chinese market. The number of linear accelerators in the country is approx. 0.6 per million inhabitants, to be compared with the recommendations by WHO of 1 per million in developing countries and 6 per million in developed countries. Through a market leadership in the advanced segment and through new offerings under development in the newly acquired Elekta BMEI, Elekta is well positioned to meet a continued strong demand in China and support the country's future development of cancer care.

Aftermarket

Elekta's aftermarket is continuing to show favorable development, partly as a result of a growing installed base. The shift towards more advanced, newly launched systems, is resulting in more customers choosing comprehensive service agreements.

Elekta continues to focus on the further development of the support and lifecycle business and on providing value based services to the expanding customer base.

Net sales

Net sales rose 4 percent to SEK 2,014 M (1,940). Elekta BMEI, acquired in August 2006, contributed with SEK 8 M. Based on unchanged exchange rates net sales rose 7 percent.

Net sales during the second quarter declined to SEK 1,018 M (1,071).



Net sales SEK M	Quarter 2 2006/07	Quarter 2 2005/06	Change	6 months 2006/07	6 months 2005/06	Change	12 months 2005/06
Europe, Middle East, Africa	426	412	3%	782	717	9%	1,608
North and South America	417	450	-7%	865	867	0%	1,971
Asia	175	209	-16%	367	356	3%	842
Group	**1,018**	**1,071**	**-5%**	**2,014**	**1,940**	**4%**	**4,421**

Earnings

Operating profit for the first half year rose 4 percent to SEK 159 M (153). The improvement was primarily a result of larger delivery volumes, the result was however negatively impacted by currency effects.

Gross margin amounted to 41 percent (42). Operating margin was 8 percent (8). On a rolling 12-month basis, operating margin was 10 percent.

Operating profit for the second quarter amounted to SEK 74 M (118) and the operating margin was 7 percent (11). The comparison is explained by lower net sales and different product mix as well as increased IFRS 2 costs during the second quarter.

According to IFRS 2 (Share-based payment) costs for Elekta's outstanding option program must be reported. In the first half year, these costs amounted to SEK 11 M (15).

Investments in research and development rose 15 percent to SEK 180 M (157) equal to 9 percent (8) of net sales. Capitalization of development costs and amortization of capitalized development costs affected earnings in the amount of SEK 8 M (6). Capitalization amounted to SEK 12 M (12) and amortization to SEK 4 M (6).

Exchange rate effects on operating profit compared to preceding year:

- Exchange rate movements affected operating profit before recorded exchange differences, negatively by about SEK 28 M.
- Recorded exchange gains in operation amounted to SEK 1 M.
- Recorded exchange losses in operation preceding year was SEK 9 M.

In total, exchange rate fluctuations compared with the preceding year affected operating profit for the first half year negatively by SEK 18 M.

Currency hedging is done on the basis of anticipated sales in foreign currency over a period of up to 24 months. Exchange rate gains from forward contracts in operating profit amounted to SEK 24 M (loss: 10). Unrealized exchange rate gains from cash flow hedges amounted to SEK 14 M and are reported in shareholders' equity, taking into account the tax effect.



Net financial items amounted to an income of SEK 1 M (loss: 5). Net interest expenses amounted to SEK 10 M (15). Shares in the earnings of associated companies amounted to SEK 10 M (8) and financial exchange rate gains to SEK 1 M (2).

Profit after net financial items rose to SEK 160 M (148). Calculated tax expense was SEK 56 M, or 35 percent. Profit after taxes amounted to SEK 104 M (98).

Earnings per share amounted to SEK 1.11 (1.04) before dilution and SEK 1.11 (1.03) after dilution.

Return on shareholders' equity amounted to 17 percent (13) and return on capital employed was 18 percent (16).

Investments and depreciation

The acquisition of BMEI resulted in an increase in intangible and tangible fixed assets of SEK 173 M. Other investments in intangible and tangible assets amounted to SEK 67 M (90). Amortization of intangible and depreciation of tangible assets amounted to SEK 65 M (82).

Liquidity and financial position

Cash flow from operating activities was negative SEK 151 M (pos. 22) during the period, in principal due to the seasonal build up of working capital. Cash flow after investments was negative SEK 343 M (neg. 51). Acquisition was included with SEK 144 M.

Liquid funds amounted to SEK 412 M compared to SEK 981 M on April 30, 2006. SEK 21 M of bank balances was pledged primarily for commercial guarantees.

Interest-bearing liabilities amounted to SEK 1,052 M compared to SEK 1,091 M on April 30, 2006. Net debt was SEK 640 M compared to SEK 110 M on April 30, 2006.

Net debt/equity ratio was 0.36 and equity/assets ratio was 35 percent.

During the first six months 132,777 new Series B shares were subscribed through the exercise of warrants distributed within the framework of the established option program.

Elekta holds 801,700 Series B shares repurchased during June-July, 2006, as part of the change in Elekta's capital structure. The Annual General Meeting has decided that the repurchased shares shall be cancelled and the cancellation process has started.

On November 30, 2006, the total number of shares was 94,514,549.

Employees

The average number of employees was 1,859 (1,694).

The number of employees on October 31, 2006 totaled 1,970 compared with 1,812 on April 30, 2006. The increase was primarily a result of the acquisition of BMEI.

Parent Company

The operations of the Parent Company include Group management and Group-wide functions, as well as financial administration. The Parent Company's loss after net financial items amounted to SEK 20 M (loss: 38). The average number of employees was 20 (20).

Acquisition of BMEI

Elekta's acquisition of 80 percent of the equity of the Chinese provider of radiation therapy equipment, Beijing Medical Equipment Institute (BMEI) and the transformation of the company into a Joint Venture (JV) is finalized, after the business license was granted by the Beijing Administration for Industry and Commerce on August 18. The acquisition value including direct acquisition costs amounted to SEK 149 M.

BMEI has its site in Chang Ping, a suburb north of Beijing, and at time of acquisition had 146 employees.

The initial accounting of the fair values to be assigned to the acquiree's identifiable assets and liabilities has been provisionally established. Intangible assets and goodwill have been valued at SEK 130 M. The intangible assets consist of technology under development and the amortization period is 5 years. Goodwill refers to future synergy effects.

The acquisition enables Elekta to meet the needs of the Chinese and other developing markets for less capital intensive equipment for radiation therapy. Elekta plans to develop the operations of BMEI through investments in research and development, production capacity and infrastructure.

The acquisition is expected to have a negative impact on Elekta's results during 2006/07. The operating loss from date of acquisition to the end of October was SEK 3 M.

Future prospects for fiscal year 2006/07 – remains unchanged

Demand for Elekta's clinical solutions, products and services are strong, while at the same time, Elekta is operating in a competitive environment. The order backlog remains on a record high level. The product portfolio is today stronger and more competitive than ever before. Elekta's leading position in IGRT together with the newly launched systems for stereotactic radiation therapy and stereotactic radiosurgery is shifting the product mix towards more advanced systems.

The acquisitions carried out during calendar year 2005 – with the intent to become a more comprehensive partner to the healthcare providers throughout the entire treatment process – continues to develop favorably.

- *For fiscal year 2006/07, Elekta expects a sales growth in line with the Group's objective of 10-15 percent in local currency.*

Elekta's operations are each year subject to substantial quarterly variations in delivery volumes, directly affecting net sales and profit. For current year, these variations are enhanced by the introduction of new advanced systems.

In 2006/07, Elekta is projecting a significant improvement in operating profit. However, customer preference and ability to accept delivery, entail uncertainties.

For the recently launched Leksell Gamma Knife® Perfexion™, the vast majority of deliveries during the fiscal year are expected to be carried in the fourth quarter. This is expected to result in substantial quarterly variations in net sales and operating margin during 2006/07. Subsequently, more than 50 percent of this year's operating profit is expected to be generated in the company's fourth quarter.

- *Operating margin for full year 2006/07 is expected to be in the range of 11-14 percent, with large quarterly variations.*

Financial information

The interim report for May-January 2006/07 will be published on March 8, 2007.

Stockholm, December 12, 2006

Elekta AB (publ)

Tomas Puusepp
President and CEO

Review Report

Elekta AB (publ), corporate registration number 556170-4015

We have reviewed the interim report for the period May 1 to October 31, 2006, for Elekta AB (publ). The board of Directors and the President are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

We conducted our review in accordance with Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by FAR. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing in Sweden, RS, and other generally accepted auditing practices.

The procedures performed in a review do not enable us to obtain a level of assurance that would make us aware of all significant matters that might be identified in an audit. Therefore, the conclusion expressed based on a review does not give the same level of assurance as a conclusion expressed based on an audit.

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not, in all material respects, prepared in accordance with IAS 34 and the Annual Accounts Act.

Stockholm, December 12, 2006

Deloitte AB

Lars Svantemark
Authorized Public Accountant

For further information, please contact:

Peter Ejemyr, Group Vice President Corporate Communications, Elekta AB (publ)
Tel: +46 733-611 000 (mobile), e-mail: peter.ejemyr@elekta.com

For more information on Elekta, please visit www.elekta.com

ELEKTA

Teleconference
In connection with this report, a teleconference will be held on December 12, at 3 p.m, Swedish time (GMT+1).

Call-in numbers:
Stockholm: +46 (0)8 5052 0110
UK: +44 (0)20 7162 0025
US: +1 334 323 6201
Paris: +33 (0)1 7099 3208
Frankfurt: +49 (0)695 8999 0507
Amsterdam: +31 (0)20 7965 008
Genève: +41 (0)2 2592 7007

(Please note: for Local Connect dial-in numbers – you might have to dial the area code to enter the conference.)

Please connect to the conference call five minutes prior to the scheduled time. Participants will be placed in a ”waiting room” until the operator declares the meeting opened.

The teleconference will be available on instant replay for 7 days. To obtain the service, please dial: Sweden: +46 8 50 520 333, UK (Europe): +44 (0) 20 7031 4064, USA: +1 954 334 0342. Access code: 729407

The teleconference on December 12 will also be available live over Internet (audio only). Follow the link from http://www.elekta.com/investors or use the direct link http://events.webeventservices.com/elekta/2006/12/12

Accounting principles

This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Financial Accounting Standards Council's recommendation RR 31 Interim Reporting for Groups and, with regard to the Parent Company, RR 32 Accounting for legal entities. Applied accounting principles and calculation methods are in accordance with the Annual Report for 2005/06.

Exchange rates		**Average rate**			**Closing rate**		
		May-Oct.	May-Oct.	Change	Oct. 31	Apr. 30,	Change
Country	Currency	2006/07	2005/06		2006	2006	
Euro	1 EUR	9.253	9.331	-1%	9.225	9.299	-1%
Great Britain	1 GBP	13.598	13.704	-1%	13.813	13.363	3%
Japan	100 JPY	6.300	6.891	-9%	6.180	6.485	-5%
United States	1 USD	7.278	7.624	-5%	7.270	7.413	-2%

INCOME STATEMENT

SEK M	3 months Aug. - Oct. 2006/07	3 months Aug. - Oct. 2005/06	6 months May - Oct. 2006/07	6 months May - Oct. 2005/06	12 months Nov.-Oct. 2005/06	12 months May - Apr. 2005/06
Net sales	1,018	1,071	2,014	1,940	4,495	4,421
Cost of products sold	-599	-610	-1,179	-1,129	-2,629	-2,579
Gross income	419	461	835	811	1,866	1,842
Selling expenses	-147	-165	-291	-311	-620	-640
Administrative expenses	-109	-93	-214	-187	-424	-397
R&D expenses	-92	-73	-172	-151	-338	-317
Exchange differences in operation	3	-12	1	-9	-25	-35
Operating profit	**74**	**118**	**159**	**153**	**459**	**453**
Result from participations in associated companies	5	4	10	8	17	15
Interest income	11	5	24	7	45	28
Interest expenses	- 17	- 14	-34	-22	-71	-59
Financial exchange differences	- 1	5	1	2	6	7
Income after financial items	**72**	**118**	**160**	**148**	**456**	**444**
Taxes	- 28	- 40	-56	-50	-146	-140
Net income	**44**	**78**	**104**	**98**	**310**	**304**
Attributable to Parent Company shareholders	44	78	104	98	310	304
Earnings per share before dilution	0.47	0.83	1.11	1.04	3.30	3.23
Earnings per share after dilution	0.48	0.82	1.11	1.03	3.29	3.21

CASH FLOW

Operating cash flow	60	97	132	162	427	457
Change in working capital	-99	55	-283	-140	-102	41
Cash flow from operating activities	**-39**	**152**	**-151**	**22**	**325**	**498**
Investments and disposals	-162	-50	-192	-73	-459	-340
Cash flow after investments	**-201**	**102**	**-343**	**-51**	**-134**	**158**
External financing	-78	231	-225	75	-233	67
Change in liquid funds	-283	382	-569	51	-383	237

BALANCE SHEET

SEK M	Oct. 31, 2006	Oct. 31, 2005	April 30, 2006
Intangible assets	2,298	2,079	2,182
Tangible fixed assets	266	222	230
Financial fixed assets	29	28	26
Inventories	439	448	364
Receivables	1,697	1,498	1,501
Liquid assets	412	795	981
Total assets	**5,141**	**5,070**	**5,284**
Shareholders' equity	1,798	1,718	1,868
Provisions	333	346	322
Interest-bearing liabilities	1,052	1,192	1,091
Interest-free liabilities	1,958	1,814	2,003
Total shareholders' equity, provisions and liabilities	**5,141**	**5,070**	**5,284**
Assets pledged	21	34	35
Contingent liabilities	120	168	127

CHANGES IN SHAREHOLDERS' EQUITY

SEK M	Oct. 31, 2006	Oct. 31, 2005	April 30, 2006
Opening balance	1,868	1,694	1,694
Changed accounting principle		11	11
IFRS 2 cost and deferred tax	9	17	25
IAS 39 unrealized cash flow hedges	3	-26	-3
Translation differences	-5	124	25
Net income	104	98	304
Option premiums and warrants exercised	8	7	19
Repurchase of shares	-100		
Dividend	-94	-207	-207
Minority's capital contribution	5		
Closing balance	1,798	1,718	1,868

ELEKTA

KEY FIGURES	12 months May - Apr. 2003/04	12 months May - Apr. 2004/05	12 months May - Apr. 2004/05*	12 months May - Apr. 2005/06	6 months May - Oct. 2005/06	6 months May - Oct. 2006/07
Order bookings, SEK M	3,262	3,558	3,558	4,705	1,997	2,302
Net sales, SEK M	2,900	3,152	3,152	4,421	1,940	2,014
Operating result, SEK M	306	349	364	453	153	159
Operating margin	11%	11%	12%	10%	8%	8%
Profit margin	11%	12%	12%	10%	8%	8%
Shareholders' equity, SEK M	1,413	1,674	1,694	1,868	1,718	1,798
Capital employed, SEK M	1,644	2,507	2,527	2,959	2,910	2,850
Equity/assets ratio	46%	37%	38%	35%	34%	35%
Net debt/equity ratio	-0.65	0.05	0.05	0,06	0,23	0,36
Return on shareholders' equity **	17%	16%	16%	17%	13%	17%
Return on capital employed **	20%	20%	21%	18%	16%	18%

* Restated according to IFRS.
** Based on rolling 12 months.

DATA PER SHARE	12 months May - Apr. 2003/04	12 months May - Apr. 2004/05	12 months May - Apr. 2004/05*	12 months May - Apr. 2005/06	6 months May - Oct. 2005/06	6 months May - Oct. 2006/07
Earnings per share						
before dilution, SEK	2.54	2.56	2.69	3.23	1.04	1.11
after dilution, SEK	2.54	2.56	2.69	3.21	1.03	1.11
Cash flow per share						
before dilution, SEK	3.71	-11.09	-11,09	1.68	-0.54	-3.66
after dilution, SEK	3.71	-11.06	-11,06	1.67	-0.54	-3.63
Shareholders' equity per share						
before dilution, SEK	15.16	17.80	18.02	19.80	18.25	19.14
after dilution, SEK	15.44	18.63	18.84	20.45	18.97	19.74
Average number of shares						
before dilution, 000s	97,756	93,991	93,991	94,136	94,068	93,841
after dilution, 000s	97,756	94,182	94,182	94,785	94,786	94,453
Number of shares at closing						
before dilution, 000s	93,199	94,028	94,028	94,332	94,143	93,663
after dilution, 000s	93,199	95,703	95,703	95,703	95,703	94,882

* Restated according to IFRS.
Dilution in 2003/04 refers to warrants program 2000/2003.
Dilution in 2004/05-2005/06 refers to warrants program 2004/2008.
All historical data restated for split 3:1 October 2005.